跳至主要内容
临床试验/NCT02653456
NCT02653456已完成不适用

A Prospective, Multi Center Pilot Study Evaluating Plaque Photoablation Using the RA-308 Excimer Laser in Subjects With Symptomatic Infrainguinal Lower Extremity Vascular Disease

Ra Medical Systems6 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2016年4月7日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
64
试验地点
6
主要终点
Crossing the Target Lesion

研究概览

简要总结

The purpose of this study is to evaluate the safety and efficacy of an excimer laser in the treatment of patients with lower extremity vascular disease with chronic total occlusions.

详细描述

The study is a multi center, prospective, non-randomized, open-label study conducted at a minimum of one investigational center. 50 subjects can be enrolled. Follow-up occurs at the end of the procedure in the form of an angiogram to determine if the lesion was crossed. Additional follow-up may not necessary because of the binary nature of the crossing, and also because any future follow-up would be assessing the effectiveness of adjunct therapy, e.g. balloon angioplasty. Long term results are entirely dependent on this subsequent treatment. Because the DABRA crosser only allows adjunct devices to be used, 30-day follow-up measuring the performance of the adjunct therapy might affect the physician's choice of therapy, and compromise the patient's treatment. Therefore, 30-day follow-up, which evaluates the effectiveness of the adjunct therapy, might raise ethical concerns. However, the follow-up can be done by Ankle-Brachial Index, Doppler ultrasound, auscultation, or by discussion of the level of claudication and motion pain with the patient. To evaluate the safety and efficacy of the RA-308 Excimer Laser System and DABRA Catheter for treating subjects with symptomatic infrainguinal lower extremity vascular disease with chronic total occlusions that cannot be crossed with standard guide wires, or lesions where an attempt to cross would, in the opinion of the interventionalist, result in either a subintimal path or a perforation.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • signed informed consent
  • symptomatic infrainguinal lower extremity vascular disease (Rutherford category 3, 4, 5 or 6), stable for at least 2 weeks prior to study inclusion
  • lesions in the superficial femoral artery (SFA), popliteal, or infrapopliteal arteries at least one angiographically identifiable infrageniculate artery
  • patients must be poor surgical candidates, indicated by at least one of the following conditions:
  • absence of venous autologous grafts (that is, lack of a suitable vein to use for bypass)
  • poor (diffusely diseased or <=1mm diameter) or no distal vessels available for graft anastamosis
  • high risk of surgical mortality, evidenced by American Society of Anesthesiologists Physical Class 4 or higher

排除标准

  • age below 18 years
  • pregnancy, or plan to become pregnant
  • participation in another cardiovascular or peripheral vascular study
  • myocardial infarction (MI) in prior month
  • stents at treatment site
  • disorders or allergies precluding use of radiographic contrast
  • renal insufficiency sever enough to contraindicate use of radiographic contrast
  • contraindication to treatment with anticoagulants
  • untreated ipsilateral iliac stenosis >70%
  • inability or unwillingness of the patient to comply with intended examinations
  • unavailability of required procedural or imaging equipment
  • lesion located in a graft
  • hemodynamically significant arrhythmia or left ventricular ejection fraction <20%
  • life expectancy less than 6 months
  • necrosis necessitating major amputation
  • unwillingness of the patient to be anti-coagulated

研究组 & 干预措施

RA-308 Excimer Laser and DABRA Catheter

Experimental

Treatment with the RA-308 excimer laser and DABRA catheter to treat chronic total occlusions that cannot be crossed with standard guidewires. The catheter and laser are a system, and cannot be used separately.

干预措施: RA-308 Excimer Laser and DABRA Catheter (Device)

结局指标

主要结局

Crossing the Target Lesion

时间窗: at time of procedure

Crossing the target lesion based on angiographic analysis

次要结局

  • Number of Participants With no Device-related Major Adverse Events(at time of procedure, up to an hour)
  • Number of Participants With Target Lesion Revascularization(6 months)

研究者

发起方
Ra Medical Systems
申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验